Profile
Gregory C.
Williams served as Chief Executive Officer & Director at Eloxx Pharmaceuticals, Inc. from 2020 to 2021.
Prior to that, he was the Chief Development Officer at Radius Health, Inc. from 2014 to 2018.
He also held positions as VP-Regulatory Affairs & Clinical Development at The Medicines Co. from 2006 to 2013 and as Vice President-Regulatory Affairs & Compliance at NPS Pharmaceuticals, Inc. from 2004 to 2006.
Williams holds a doctorate from Rutgers State University of New Jersey and an MBA from Cornell University.
Former positions of Gregory C. Williams
| Companies | Position | End |
|---|---|---|
| ELOXX PHARMACEUTICALS, INC. | Chief Executive Officer | 31/03/2021 |
| RADIUS HEALTH, INC. | Corporate Officer/Principal | 24/05/2018 |
| THE MEDICINES COMPANY | Chief Tech/Sci/R&D Officer | 31/12/2012 |
| NPS PHARMACEUTICALS, INC. | Compliance Officer | 31/12/2005 |
Training of Gregory C. Williams
| Rutgers State University of New Jersey | Doctorate Degree |
| Cornell University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ELOXX PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Gregory C. Williams
